Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Boule Diagnostics – Invitation to presentation of the interim report Q1 2024

Boule Diagnostics AB will publish the interim report for the period January–March 2024 at 07:30, Tuesday, May 7th, 2024. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and CFO Holger Lembrér will present and comment on the first quarter report. After the presentation there will be time for audience questions. The presentation will be held in English. The interim report will be accessible at www.boule.com when published. Please feel free to attend this event! Time:             10.00 CEST, Tuesday, May 7th, 2024

Tradedoubler annual report 2023 published

Tradedoubler has as of today published the annual report 2023. The annual report is prepared in Swedish and translated into English. Both versions are available at Tradedoubler’s website, see the following link: https://www.tradedoubler.com/en/investors/financial-information-and-publications/ For further information, please contact: Matthias Stadelmeyer, CEO TradedoublerPhone: +46 8 405 08 00Email: ir@tradedoubler.com About this information This information is information that Tradedoubler AB is obliged to make public pursuant to the Swedish Securities Markets Act. The

Etteplan’s January-March 2024 interim report to be published on May 8, 2024

ETTEPLAN OYJ, Investor News, April 30, 2024, at 1.00 p.m. Etteplan’s January-March 2024 interim report to be published on May 8, 2024 Etteplan Oyj will publish its January-March 2024 interim report on Wednesday May 8, 2024 at approximately 1.00 p.m. Finnish time (EEST). The release and related presentation material will be available in Finnish and in English on the Company’s website at www.etteplan.com  after the publishing. Conference call and live webcast Etteplan’s President and CEO Juha Näkki will present the Company’s result for January-

Polar Vantage V3 wins the Red Dot Award for Product Design

Polar, the leader in wearable sports and fitness technology for nearly 50 years, has been awarded the prestigious Red Dot Award for Product Design. Widely considered one of the most prominent honors in the global design sector, the award was granted to Polar Vantage V3 premium multisport watch for its outstanding design, functionality and innovation. This is yet another accolade for Vantage V3, which won earlier this year the internationally respected iF DESIGN AWARD. An international judging panel consisting of top design experts selected Vantage V3 as the winner of the Red Dot Design

UPM Raflatac unveils Carbon Action portfolio to drive action towards a low carbon circular economy

(UPM Raflatac, Helsinki, 30 April 2024 at 13:00 EEST) – According to the UN, today only 15% of the Sustainable Development Goal targets are on track. In September 2023, UPM joined the UN Global Compact Forward Faster initiative to accelerate this pace. To demonstrate its commitment to the Climate Action initiative and help its customers reduce the carbon footprint of their packaging materials and drive action, UPM Raflatac is proud to announce the launch of its Carbon Action Plastic Labels portfolio. From 30th April 2024, the first products offered under the Carbon Action

Photocure ASA: Annual Report 2023

Oslo, Norway, 30 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.The Board of Directors of Photocure ASA has approved the annual accounts for 2023. The financial statements and annual report for the financial year 2023 are together with the ESG report and auditor's report attached to this notice. The ESEF file for 2023 is also attached. The documents are enclosed and also made available at the company's website under https://photocure.com/investors-hub/investors-events-and-presentations. For further information, please

Brain+ releases preliminary annual financial statements for 2023

Copenhagen, Denmark, 30 April 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  ·Brain+’ preliminary financial results for 2023 shows a gross profit of DKK 2.4 million and a net result of DKK -19.1 million  ·Brain+’ management has maintained a tight cost control to extend the company’s financial runway as much as possible and ensure operational momentum in its early phase of product commercialization  ·On 31 December 2023, the company’s cash and cash equivalents amounted to DKK 3.1 million.   ·In March 2024, Brain+ raised DKK 2.5 million in net proceeds from a 91%

Decisions of the Annual General Meeting of Nokian Tyres plc

Nokian Tyres plc Stock Exchange Release April 30, 2024 at 12:50 p.m. EEST Nokian Tyres plc’s (“Nokian Tyres” or the “Company”) Annual General Meeting (the “General Meeting”) was held at Messukeskus in Helsinki, Finland today, on April 30, 2024. The General Meeting adopted the financial statements for 2023, discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2023 and adopted the Company’s Remuneration Report and Remuneration Policy for governing bodies. The General Meeting also decided on the payment of dividend as well as

BioInvent evaluating Attana Technology

BioInvent and Attana has signed a three-month evaluation agreement. BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Based on extensive knowledge in immunology, cancer biology and antibody biology, BioInvent generates innovative immuno-oncology drug candidates.Attana will in May install Attana Cell™ 250 instrument and train users at BioInvents labs in Lund. During the evaluation period cell- and sera-based assays will be performed to study interactions between antibodies and target cells.

Chordate's board member to BioStock: "Women's health is a concern for society at large"

Caroline Brandberg, a Chordate Medical board member, participated in Feminvest's event FEARLESS in Oslo on April 25th. During the event, she presented the company's treatment method Ozilia for chronic migraine – a condition that tends to affect women more than men.– Migraine is one of the leading conditions among women. To address this, more treatment options are needed, which must be made available and affordable in order for all women to have access to adequate care,  says Brandberg.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/

EndoDrill presented as New Kid on the Block at ESGE Days

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, informs about the international endoscopy congress in Berlin, ESGE Days, where EndoDrill[®] GI was named “New Kid on the Block”. The recognition was made at the session called “EUS Novelties in EUS Tissue Acquisition", led by Dr. Livia Archibugi from IRCCS San Raffaele Hospital in Milano, who referred to BiBB’s proming published data on EndoDrill[®] GI. At the same congress, BiBB's users from Sweden and the US had a

edyoutec - Wegesrand and Austrian edtech-provider ovos sign cooperation agreement

Press release April 30, 2024 edyoutec’s subsidiary Wegesrand and ovos media GmbH, based in Austria, have agreed on a strategic sales partnership. Both companies specialise in interactive knowledge transfer.Ovos has been active as a provider of playful learning content for 20 years. With "ovos play", the company has developed an award-winning tool for producing, managing and operating playful learning content and gamification. In the concluded framework agreement, Wegesrand is licensing this highly innovative tool and thus opening up for a more standardized workflow when it comes to

New drug candidate reverses obesity in mice

Researchers at Karolinska Institutet may have found a new way to treat obesity and related disorders by targeting the cells’ powerhouses, the mitochondria. A study published in Nature Metabolism shows that a specific class of drugs that block mitochondrial function can reverse diet-induced obesity, fatty liver and diabetes in mice.Mitochondria are essential for human health, as they process the nutrients in the food we eat and harvest the energy needed for various processes in the cell. They are central regulators of metabolism, which is very dynamic and can be rerouted and reprogrammed

Invitation to a presentation of ITAB’s Interim Report for the first quarter 2024

ITAB Shop Concept AB (publ) (“ITAB”) will publish its Interim Report for the first quarter 2024 on Tuesday, 14 May 2024 at 7:00 a.m. CEST. In conjunction with this, ITAB are pleased to issue this invitation to a webcast presentation in which President & CEO Andréas Elgaard and CFO Ulrika Bergmo Sköld will present the report and answer any subsequent questions.DATE: Tuesday, 14 May 2024 TIME: 10:30 a.m. CEST WEBCAST: To participate via webcast – please use the weblink below. Via the webcast you are able to ask questions in writing.https://ir.financialhearings.com/itab-shop-concept-q1-

Change in number of shares and votes in Evolution AB (publ)

During April 2024, 200 new shares in Evolution AB (publ) have been issued through the exercise of 200 warrants of series 2021/2024. As of 30 April 2024, following the exercise of the warrants set out above, the number of shares and votes in Evolution AB (publ) amounts to 216,398,707. For investor enquiries, please contact:Jacob Kaplan, CFO, ir@evolution.com. This information is such that Evolution AB (publ) is obliged to publish according to the Swedish Financial Instruments Trading Act. This press release was submitted for publication by the person above on 30 April 2024 at 11:

Metsä Board Corporation: Managers’ transactions (Hämälä, Ilkka)

Metsä Board Corporation Stock Exchange Release Decisions of general meeting 30 April 2024 at 12:00 noon EESTThe Annual General Meeting of Metsä Board Corporation held on 26 March 2024 decided that one half of the Board’s annual remuneration is paid in the Company’s B-series shares. Pursuant to such decision, the following shares have been acquired for and on behalf of the Chair of the Board Ilkka Hämälä: Metsä Board Corporation - Managers' transactions - Hämälä____________________________________________ Person subject to the notification requirementName: Hämälä, IlkkaPosition:

Metsä Board Corporation: Managers’ transactions (Hankonen-Nybom, Raija-Leena)

Metsä Board Corporation Stock Exchange Release Decisions of general meeting 30 April 2024 at 12:00 noon EESTThe Annual General Meeting of Metsä Board Corporation held on 26 March 2024 decided that one half of the Board’s annual remuneration is paid in the Company’s B-series shares. Pursuant to such decision, the following shares have been acquired for and on behalf of the Board member Raija-Leena Hankonen-Nybom: Metsä Board Corporation - Managers' transactions - Hankonen-Nybom____________________________________________ Person subject to the notification requirementName: Hankonen-

Metsä Board Corporation: Managers’ transactions (Hyrsky, Erja)

Metsä Board Corporation Stock Exchange Release Decisions of general meeting 30 April 2024 at 12:00 noon EESTThe Annual General Meeting of Metsä Board Corporation held on 26 March 2024 decided that one half of the Board’s annual remuneration is paid in the Company’s B-series shares. Pursuant to such decision, the following shares have been acquired for and on behalf of the Board member Erja Hyrsky: Metsä Board Corporation - Managers' transactions - Hyrsky____________________________________________ Person subject to the notification requirementName: Hyrsky, ErjaPosition: Member

Metsä Board Corporation: Managers’ transactions (Kiviniemi, Mari)

Metsä Board Corporation Stock Exchange Release Decisions of general meeting 30 April 2024 at 12:00 noon EESTThe Annual General Meeting of Metsä Board Corporation held on 26 March 2024 decided that one half of the Board’s annual remuneration is paid in the Company’s B-series shares. Pursuant to such decision, the following shares have been acquired for and on behalf of the Board member Mari Kiviniemi: Metsä Board Corporation - Managers' transactions - Kiviniemi____________________________________________ Person subject to the notification requirementName: Kiviniemi, MariPosition:

Metsä Board Corporation: Managers’ transactions (Mäkimattila, Mikko)

Metsä Board Corporation Stock Exchange Release Decisions of general meeting 30 April 2024 at 12:00 noon EESTThe Annual General Meeting of Metsä Board Corporation held on 26 March 2024 decided that one half of the Board’s annual remuneration is paid in the Company’s B-series shares. Pursuant to such decision, the following shares have been acquired for and on behalf of the Board member Mikko Mäkimattila: Metsä Board Corporation - Managers' transactions - Mäkimattila____________________________________________ Person subject to the notification requirementName: Mäkimattila, Mikko

Metsä Board Corporation: Managers’ transactions (Moisio, Jukka)

Metsä Board Corporation Stock Exchange Release Decisions of general meeting 30 April 2024 at 12:00 noon EESTThe Annual General Meeting of Metsä Board Corporation held on 26 March 2024 decided that one half of the Board’s annual remuneration is paid in the Company’s B-series shares. Pursuant to such decision, the following shares have been acquired for and on behalf of the Board member Jukka Moisio: Metsä Board Corporation - Managers' transactions - Moisio____________________________________________ Person subject to the notification requirementName: Moisio, JukkaPosition: Member

There are no items matching the current filter
There are no more items matching the current filter
Back to top